Regarding biomarkers, the neurofilament light chain (NfL) is currently a sensitive and commonly used marker, and serum NfL has been used as a biomarker of early stage and disease progression to guide clinical trials for ALS (Benatar et al., 2018, 2023). The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.